Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vishnu Prasath

Showing results (41-50 of 41) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 41 results.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
Pageof 5

Showing results (41-50 of 41) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 41 results.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
Pageof 5